Acrivon Therapeutics (ACRV) Operating Expenses (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Operating Expenses for 6 consecutive years, with $18.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 17.58% year-over-year to $18.7 million in Q2 2026; TTM through Jun 2026 was $78.4 million, a 16.98% decrease from a year earlier, with the FY2025 full-year figure at $84.1 million, down 5.7% from the prior year.
• Operating Expenses was $18.7 million for Q2 2026 at Acrivon Therapeutics, down from $19.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $25.1 million in Q3 2024 and troughed at $5.9 million in Q2 2022.
• A 5-year average of $17.3 million and a median of $19.2 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 258.48% in 2022 and declined 21.69% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $9.9 million in 2022, then soared by 111.69% to $21.1 million in 2023, then rose by 18.53% to $25.0 million in 2024, then decreased by 19.39% to $20.1 million in 2025, then dropped by 7.2% to $18.7 million in 2026.
• The last three Operating Expenses figures came in at $18.7 million (Q2 2026), $19.9 million (Q1 2026), and $20.1 million (Q4 2025), per Business Quant data.